Navigation Links
Cornerstone Pharmaceuticals to Present New Data on CPI-613 at the American Society of Hematology 2016 Annual Meeting
Date:11/21/2016

CRANBURY, N.J., Nov. 21, 2016 /PRNewswire/ --

WHAT: CPI-613 is Cornerstone Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting mitochondrial metabolism. It selectively targets the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell proliferation and survival. The two datasets are from the first reported studies of CPI-613-based combination therapies in patients with AML and T-cell NHL. 

ASH Abstract Details:

  • TCA Cycle Inhibition by CPI-613 Increases Sensitivity to Chemotherapy in Older and Poor Risk Acute Myeloid Leukemia (AML)
    • Date/Time: Monday, December 5, 2016 6:00-8:00 PM PT
    • Session: 616. Acute Myeloid Leukemia: Novel Therapy, Excluding Transplantation: Poster III
    • Location: San Diego Convention Center, Hall GH
    • Abstract #: 4062
    • Scheduled Presenter: Timothy S. Pardee, M.D. Ph.D., Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston-Salem, N         
  • Phase I Dose-Escalation Study of CPI-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
    • Date/Time: Monday, December 5, 2016, 6:00-8:00 PM PT
    • Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Poster III
    • Location: San Diego Convention Center, Hall GH
    • Abstract #: 4163
    • Scheduled Presenter: Zanetta S. Lamar, M.D., Department of Hematology / Oncology, Wake Forest Baptist Medical Center, Winston-Salem, NC

WHO: Drs. Pardee and Lamar (primary investigators) will be available for media interviews upon request

WHERE: American Society of Hematology Annual Meeting, San Diego Convention Center, San Diego, California

CONTACT: Kara Golub, 609-456-0822 or kgolub@jfkhealth.com, for more information.

About Cornerstone Pharmaceuticals, Inc.

Cornerstone Pharmaceuticals, Inc. is a privately held, clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's investors include IDT Corporation (NYSE: IDT). Cornerstone's primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Cornerstone's first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has designated CPI-613 an orphan drug for the treatment of acute myeloid leukemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS).www.cornerstonepharma.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cornerstone-pharmaceuticals-to-present-new-data-on-cpi-613-at-the-american-society-of-hematology-2016-annual-meeting-300366293.html


'/>"/>
SOURCE Cornerstone Pharmaceuticals
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon
2. HelpMeSee & Cornerstone Assistance Showcase MSICS In Texas
3. Cornerstone Therapeutics Inc. Stockholders Seeking More Money Regarding the Proposed Buyout by Chiesi Farmaceutici S.P.A. Encouraged to Contact Lawyers at Deans & Lyons
4. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
5. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ligand Pharmaceuticals Incorporated (LGND) and Lead Plaintiff Deadline: January 17, 2017
6. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alexion Pharmaceuticals, Inc. (ALXN) and Lead Plaintiff Deadline: January 17, 2017
7. Atrin Pharmaceuticals Elects Jeffrey M. Dayno, MD to Board of Directors
8. FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
9. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
10. Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx
11. Vanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... MIRADA, Calif. (PRWEB) , ... August 16, 2019 ... ... their new psychological service, Eye Movement Desensitization and Reprocessing therapy (EMDR). This therapeutic ... EMDR is an evidence-based practice used for post-traumatic stress disorder (PTSD), depression, chronic ...
(Date:8/16/2019)... ... August 16, 2019 , ... Sacramento-based physician recruiting firm, MDstaffers , ... by Inc. magazine. MDstaffers three-year growth of more than 5,600 percent made it the ... human resources company had it competed in this category. This news comes nine-years after ...
(Date:8/16/2019)... ... August 16, 2019 , ... Today, Point-of-Care Partners announced Government ... has joined the company as a Government Affairs and Health IT Strategist. In ... standards organizations to advance use of health IT for comprehensive medication management. , ...
Breaking Medicine Technology:
(Date:8/19/2019)... , ... August 19, 2019 , ... ... selling Eminence Organic Skin Care products , the authorized retailer will change ... DeVries, was a practicing esthetician in Florida providing Eminence Organic Skin Care facials ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... Houston and San Antonio, Texas, proudly announces they have ranked #3056 on the ... ranking and represents a unique look at the most successful companies within the ...
(Date:8/19/2019)... ANGELES (PRWEB) , ... August 18, 2019 , ... ... Morning Recovery, today launches its third product, Aqua+, adding two SKUs to its ... hydrate users faster and more effectively than water alone. Distinguishing Aqua+ from other ...
(Date:8/16/2019)... ... August 16, 2019 , ... Inc. magazine ... list, the most prestigious ranking of the nation’s fastest-growing private companies. The list ... most dynamic segment—its independent small businesses. Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, ...
(Date:8/16/2019)... HYDE PARK, N.Y. (PRWEB) , ... August 16, ... ... designed, fabricated, and donated a custom handcrafted, one-of-a-kind children’s aircraft to Ronald McDonald ... was designed to give children residents undergoing medical treatments and their family ...
Breaking Medicine News(10 mins):